ES2526352T3 - Derivados de piridazinona - Google Patents

Derivados de piridazinona Download PDF

Info

Publication number
ES2526352T3
ES2526352T3 ES08758359T ES08758359T ES2526352T3 ES 2526352 T3 ES2526352 T3 ES 2526352T3 ES 08758359 T ES08758359 T ES 08758359T ES 08758359 T ES08758359 T ES 08758359T ES 2526352 T3 ES2526352 T3 ES 2526352T3
Authority
ES
Spain
Prior art keywords
nhet
conr3
nhconh
atoms
nhet1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08758359T
Other languages
English (en)
Spanish (es)
Inventor
Dieter Dorsch
Frank Stieber
Oliver Schadt
Andree Blaukat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2526352T3 publication Critical patent/ES2526352T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
ES08758359T 2007-07-12 2008-04-29 Derivados de piridazinona Active ES2526352T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007032507 2007-07-12
DE102007032507A DE102007032507A1 (de) 2007-07-12 2007-07-12 Pyridazinonderivate
PCT/EP2008/003473 WO2009006959A1 (de) 2007-07-12 2008-04-29 Pyridazinonderivate

Publications (1)

Publication Number Publication Date
ES2526352T3 true ES2526352T3 (es) 2015-01-09

Family

ID=39638671

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08758359T Active ES2526352T3 (es) 2007-07-12 2008-04-29 Derivados de piridazinona
ES14001269T Active ES2614283T3 (es) 2007-07-12 2008-04-29 Derivados de piridazinona
ES08773881T Active ES2388883T3 (es) 2007-07-12 2008-07-04 Derivados de pirimidinil-piridazinona

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES14001269T Active ES2614283T3 (es) 2007-07-12 2008-04-29 Derivados de piridazinona
ES08773881T Active ES2388883T3 (es) 2007-07-12 2008-07-04 Derivados de pirimidinil-piridazinona

Country Status (36)

Country Link
US (8) US8580781B2 (OSRAM)
EP (3) EP2754660B1 (OSRAM)
JP (2) JP5426543B2 (OSRAM)
KR (2) KR101553418B1 (OSRAM)
CN (2) CN101743241B (OSRAM)
AR (2) AR066543A1 (OSRAM)
AU (2) AU2008274670B2 (OSRAM)
BR (2) BRPI0814616B1 (OSRAM)
CA (2) CA2693600C (OSRAM)
CL (1) CL2008001392A1 (OSRAM)
CO (2) CO6170360A2 (OSRAM)
CY (4) CY1113137T1 (OSRAM)
DE (1) DE102007032507A1 (OSRAM)
DK (3) DK2754660T3 (OSRAM)
EA (2) EA016782B1 (OSRAM)
EC (2) ECSP109953A (OSRAM)
ES (3) ES2526352T3 (OSRAM)
FR (1) FR22C1024I2 (OSRAM)
HR (3) HRP20150031T1 (OSRAM)
HU (2) HUE030519T2 (OSRAM)
IL (2) IL203091A (OSRAM)
LT (2) LT2754660T (OSRAM)
LU (1) LUC00264I2 (OSRAM)
MY (2) MY153727A (OSRAM)
NL (1) NL301176I2 (OSRAM)
NO (1) NO2022015I1 (OSRAM)
NZ (1) NZ583187A (OSRAM)
PE (1) PE20090287A1 (OSRAM)
PL (3) PL2754660T3 (OSRAM)
PT (3) PT2754660T (OSRAM)
SG (1) SG183739A1 (OSRAM)
SI (3) SI2754660T1 (OSRAM)
TW (1) TWI501768B (OSRAM)
UA (2) UA99621C2 (OSRAM)
WO (2) WO2009006959A1 (OSRAM)
ZA (1) ZA201001023B (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007041115A1 (de) * 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UA103646C2 (ru) * 2008-12-22 2013-11-11 Мерк Патент Гмбх Полиморфные формы 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илетокси)-пиримидин-2-ил]-бензил}-2h-пиридазин-3-она и способ их получения (варианты)
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
DE102009003954A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
CA2749012C (en) 2009-01-08 2017-01-31 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
EP2221053A1 (de) * 2009-02-20 2010-08-25 Albert-Ludwigs-Universität Freiburg Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
DE102011101482B4 (de) 2011-05-13 2017-05-11 Thyssenkrupp Presta Aktiengesellschaft Sensoranordnung für eine drehbare Welle
WO2013139423A1 (en) 2012-03-19 2013-09-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
KR101842645B1 (ko) 2012-04-12 2018-03-29 한국화학연구원 신규한 히드라진온이 치환된 피리미딘 유도체 및 그의 용도
CN104703655A (zh) * 2012-10-11 2015-06-10 默克专利股份公司 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合
KR102131588B1 (ko) * 2012-11-02 2020-07-08 메르크 파텐트 게엠베하 간세포 암종 (hcc) 의 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
MX364486B (es) * 2013-02-07 2019-04-29 Merck Patent Gmbh Derivados de piridazinona-amidas.
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
CN105492439B (zh) 2013-06-21 2019-11-22 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的取代的双环化合物
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
CA3148196A1 (en) * 2013-10-18 2015-04-23 Celgene Quanticel Research, Inc. Bromodomain inhibitors
PL3077047T3 (pl) * 2013-12-04 2019-10-31 Galmed Res & Development Ltd Sole aramcholu
JP2017502978A (ja) * 2014-01-07 2017-01-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腎細胞癌（ｒｃｃ）の処置のための使用のための６−オキソ−１，６−ジヒドロ−ピリダジン誘導体
RU2016132400A (ru) * 2014-01-07 2018-02-13 Мерк Патент Гмбх Комбинация производного 6-оксо-1,6-дигидро-пиридазина, имеющего противораковую активность, с гефитинибом
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
EP3785714A1 (en) * 2014-04-01 2021-03-03 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
US9642794B2 (en) * 2014-08-18 2017-05-09 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
MX376993B (es) * 2014-12-11 2025-03-07 Merck Patent Gmbh Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un derivado de quinazolina.
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
MX2017007372A (es) * 2014-12-12 2017-11-06 Merck Patent Gmbh Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un inhibidor de factor de crecimiento epidermico (egfr).
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016192831A1 (en) 2015-05-29 2016-12-08 Merck Patent Gmbh Compositions of anions and cations with pharmacological activity
CN107920990A (zh) 2015-06-15 2018-04-17 塔米尔生物技术公司 用于治疗眼睛的病毒性感染的药物
PT3533787T (pt) 2016-10-27 2020-11-20 Fujian Cosunter Pharmaceutical Co Ltd Composto de piridona como inibidor de c-met
JP2020502058A (ja) * 2016-11-18 2020-01-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ジアシルグリセリドｏ−アシルトランスフェラーゼ２の阻害薬として有用なインダゾール誘導体
CN111194215B (zh) 2017-08-04 2024-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3697776B1 (en) 2017-10-17 2023-04-19 Palau Pharma, S.L.U. Synthesis of 4-aminopyrimidine compounds
EP3719012B1 (en) 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
EA039713B1 (ru) * 2018-04-26 2022-03-03 Фуцзянь Косантер Фармасьютикал Ко., Лтд. Кристаллическая форма ингибитора c-met, его солевая форма и способ их получения
CN108752322A (zh) * 2018-09-12 2018-11-06 广州新民培林医药科技有限公司 一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用
SMT202300355T1 (it) 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
JP7671245B2 (ja) 2018-11-06 2025-05-01 エッジワイズ セラピューティクス， インコーポレイテッド ピリダジノン化合物およびその使用
CA3118908A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
JP7214879B2 (ja) * 2019-02-01 2023-01-30 メッドシャイン ディスカバリー インコーポレイテッド ｃ－Ｍｅｔ阻害剤としてのピリミジニルを含むトリシクリル系化合物
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
US20220152031A1 (en) * 2019-03-20 2022-05-19 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
CN118986988A (zh) 2019-07-10 2024-11-22 默克专利股份公司 药物制剂
WO2021027943A1 (zh) * 2019-08-14 2021-02-18 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
WO2022250350A1 (ko) * 2021-05-26 2022-12-01 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
KR102489160B1 (ko) * 2021-05-26 2023-01-18 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
AU2022286643A1 (en) 2021-06-04 2024-01-18 Merck Patent Gmbh Compounds for the treatment of glioblastoma
JP2024540485A (ja) * 2021-11-17 2024-10-31 エッジワイズ セラピューティクス， インコーポレイテッド ピリダジノン化合物およびその使用
CN114394957B (zh) * 2021-12-24 2023-05-09 武汉九州钰民医药科技有限公司 Met抑制剂盐酸特泊替尼的制备方法
IL318241A (en) 2022-07-08 2025-03-01 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment
CN116496253B (zh) * 2022-08-19 2024-10-11 中国人民解放军军事科学院军事医学研究院 c-MET蛋白靶向降解剂及其医药应用
CN115583939A (zh) * 2022-11-04 2023-01-10 苏州莱安医药化学技术有限公司 一种特泊替尼中间体的合成方法
KR20240076745A (ko) * 2022-11-22 2024-05-30 주식회사 이노큐어테라퓨틱스 신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물
KR20240075764A (ko) * 2022-11-22 2024-05-29 주식회사 이노큐어테라퓨틱스 cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
CN116082309B (zh) * 2023-01-04 2023-10-24 广东莱恩医药研究院有限公司 嘧啶衍生物1d228盐酸盐晶型及其制备方法和应用
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用
CN118084871B (zh) * 2024-04-29 2024-07-09 中国药科大学 一种靶向降解c-Met蛋白的化合物及其制法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853946A (en) 1971-11-11 1974-12-10 Hoffmann La Roche Process for the preparation of aminomethylene malononitrile
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
RU2209813C2 (ru) 1997-11-19 2003-08-10 Кова Ко., Лтд. Производные пиридазина, лекарственные средства на их основе и способ лечения артрита
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
DE10010422A1 (de) 2000-03-03 2001-09-06 Bayer Ag 6-Carboxyphenylpyridazinon-Derivate und ihre Verwendung
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
CN1578665A (zh) 2001-10-31 2005-02-09 默克专利股份公司 4型磷酸二脂酶抑制剂及其应用
BR0306988A (pt) * 2002-01-18 2004-11-23 Pharmacia Corp Piridazinonas substituìdas como inibidores de p38
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
CA2510298A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
CA2530589A1 (en) 2003-07-02 2005-01-20 Sugen Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
DE102005055354A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
EP1966214B9 (en) 2005-12-21 2017-09-13 Janssen Pharmaceutica N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2009050197A2 (en) 2007-10-16 2009-04-23 Novartis Ag Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
US8440666B2 (en) 2007-10-31 2013-05-14 Nissan Chemical Industries, Ltd. Pyridazinone compounds and P2X7 receptor inhibitors
TW200927115A (en) 2007-11-16 2009-07-01 Boehringer Ingelheim Int Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
PE20091669A1 (es) 2007-12-21 2009-12-06 Exelixis Inc Benzofuropirimidinonas
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
EP2242483B1 (en) 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
ES2526649T3 (es) 2007-12-21 2015-01-14 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
BRPI0821141A2 (pt) 2007-12-21 2015-06-16 Hoffmann La Roche Derivados de heteroarila como antagonistas do receptor de orexina
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
PT2235012E (pt) 2007-12-21 2013-08-28 Palau Pharma Sa Derivados de 4-aminopirimidina como antagonistas de receptor h4 de histamina
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
CN101538245B (zh) * 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) * 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EP2323994A1 (en) * 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
US20120028988A1 (en) * 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
AU2008274670B2 (en) 2013-03-14
CN101687857A (zh) 2010-03-31
BRPI0814616A2 (pt) 2015-01-27
LUC00264I2 (OSRAM) 2025-04-25
ECSP109953A (es) 2010-03-31
HRP20150031T1 (xx) 2015-03-13
CA2693600C (en) 2015-10-06
PL2164844T3 (pl) 2012-10-31
BRPI0813707A2 (pt) 2014-12-30
NL301176I2 (nl) 2022-11-03
CY1115925T1 (el) 2017-01-25
LTC2164843I2 (OSRAM) 2023-12-11
US20150133452A1 (en) 2015-05-14
PT2164843E (pt) 2014-12-23
CY1113137T1 (el) 2016-04-13
CA2692867C (en) 2016-05-24
TW200906409A (en) 2009-02-16
ES2388883T3 (es) 2012-10-19
US8580781B2 (en) 2013-11-12
EP2164844B1 (de) 2012-06-27
CL2008001392A1 (es) 2009-01-23
US9284300B2 (en) 2016-03-15
UA99833C2 (en) 2012-10-10
ZA201001023B (en) 2010-11-24
SG183739A1 (en) 2012-09-27
LT2754660T (lt) 2016-12-12
JP5426544B2 (ja) 2014-02-26
US9062029B2 (en) 2015-06-23
UA99621C2 (xx) 2012-09-10
US20100234354A1 (en) 2010-09-16
US8921357B2 (en) 2014-12-30
US8658643B2 (en) 2014-02-25
EP2164843A1 (de) 2010-03-24
EP2164843B1 (de) 2014-10-29
PL2164843T3 (pl) 2015-03-31
TWI501768B (zh) 2015-10-01
KR101544624B1 (ko) 2015-08-17
CY2022017I2 (el) 2023-01-05
NL301176I1 (OSRAM) 2022-06-01
CN101687857B (zh) 2013-07-17
US20100197690A1 (en) 2010-08-05
US20130184261A1 (en) 2013-07-18
ECSP109957A (es) 2010-03-31
MY153727A (en) 2015-03-13
SI2164843T1 (sl) 2015-02-27
JP2010532774A (ja) 2010-10-14
HRP20120661T1 (hr) 2012-09-30
FR22C1024I2 (fr) 2023-03-24
WO2009007074A1 (de) 2009-01-15
DK2164843T3 (en) 2014-12-01
ES2614283T3 (es) 2017-05-30
HK1142891A1 (en) 2010-12-17
PE20090287A1 (es) 2009-03-19
PT2164844E (pt) 2012-08-31
CN101743241B (zh) 2013-12-25
IL203091A (en) 2013-10-31
BRPI0814616B1 (pt) 2022-04-19
US20140128396A1 (en) 2014-05-08
US20150011534A1 (en) 2015-01-08
US9403799B2 (en) 2016-08-02
DK2754660T3 (en) 2017-02-13
KR20100050504A (ko) 2010-05-13
PL2754660T3 (pl) 2017-05-31
NO2022015I1 (no) 2022-05-13
IL203094A (en) 2013-08-29
US8329692B2 (en) 2012-12-11
CY1118498T1 (el) 2017-07-12
SI2754660T1 (sl) 2017-03-31
BRPI0813707B1 (pt) 2022-02-22
AU2008274534B2 (en) 2013-05-30
HUE030519T2 (en) 2017-05-29
JP2010532768A (ja) 2010-10-14
WO2009006959A1 (de) 2009-01-15
CA2693600A1 (en) 2009-01-15
MY163477A (en) 2017-09-15
AR066543A1 (es) 2009-08-26
CY2022017I1 (el) 2023-01-05
HUS2200024I1 (hu) 2022-06-28
EA016782B1 (ru) 2012-07-30
EP2754660A1 (de) 2014-07-16
FR22C1024I1 (fr) 2022-07-22
US20130184260A1 (en) 2013-07-18
AU2008274670A1 (en) 2009-01-15
DK2164844T3 (da) 2012-08-20
EP2754660B1 (de) 2016-11-02
AR067505A1 (es) 2009-10-14
PT2754660T (pt) 2017-02-10
AU2008274534A1 (en) 2009-01-15
NZ583187A (en) 2011-10-28
CO6170360A2 (es) 2010-06-18
CO6270257A2 (es) 2011-04-20
DE102007032507A1 (de) 2009-04-02
CA2692867A1 (en) 2009-01-15
US20120295908A1 (en) 2012-11-22
SI2164844T1 (sl) 2012-10-30
KR101553418B1 (ko) 2015-09-15
CN101743241A (zh) 2010-06-16
EA201000094A1 (ru) 2010-06-30
LTPA2022009I1 (OSRAM) 2022-06-10
US8927540B2 (en) 2015-01-06
HK1145265A1 (en) 2011-04-08
JP5426543B2 (ja) 2014-02-26
EA201000093A1 (ru) 2010-06-30
HRP20170100T1 (hr) 2017-03-24
EP2164844A1 (de) 2010-03-24
EA017281B1 (ru) 2012-11-30
KR20100031771A (ko) 2010-03-24

Similar Documents

Publication Publication Date Title
ES2526352T3 (es) Derivados de piridazinona
AR057214A1 (es) Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.
AR068659A1 (es) Derivados de imidazol inhibidores de autotaxina
AR068658A1 (es) Derivados de tiazol
AR068748A1 (es) Derivados de piridina activadores de glucoquinasa
AR090867A1 (es) Compuestos y composiciones plaguicidas y procesos relacionados
AR066769A1 (es) Derivados de arileter-piridazinona
AR113842A1 (es) Derivados de tiazol microbiocidas
AR088534A1 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
CO6180441A2 (es) Inhibidores nucleosidos del hcv
AR077567A1 (es) Derivados de aminopiridina
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
AR085410A1 (es) Derivados de pirazol heteroaril-sustituidos, composiciones pesticidas que los comprenden y su uso en el control de plagas
AR092211A1 (es) Derivados de hidropirrolopirrol
AR076006A1 (es) Compuestos heterociclicos inhibidores de autotaxina utiles para el tratamiento de tumores, proceso para prepararlos y medicamentos que los contienen.
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
AR073369A1 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR068749A1 (es) Derivados de n-(pirazol-3-il)-benzamida
AR075122A1 (es) Derivados de piridazinona
AR069843A1 (es) Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento
AR072860A1 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
AR067081A1 (es) Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales.
AR095422A1 (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
AR072192A1 (es) Derivados de tiazolil-piperidina